BIOX 6-K SEC Filing Analysis

Latest settled — T+5d

BIOX ▼ -12.50% at T+5d

NEUTRAL call ✗ call lost -12.50% · α vs SPY -9.75% · entry $0.4800 → $0.4200

Next anchor: T+20d in 15d

Last close $0.4200 (close Jun 12) · -12.50% from $0.4800 entry

Entry anchored
May 29, 03:59 PM ET
via Databento tick

T+1d

+2.29%

call +2.29% · α +2.15%

$0.4910

settled 13d ago

T+5d

-12.50%

call -12.50% · α -9.75%

$0.4200

settled 7d ago

T+20d

—

call — · α —

—

in 15d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Bioceres Crop Solutions Corp. subsidiary Rizobacter completed an exchange offer and consent solicitation on ~86% of ~$42.7M in outstanding Series IX and X notes, extending maturities as part of broader liability management. This reduces near-term refinancing risk for a key subsidiary but does not address the parent company's $28M market cap or underlying operational performance.

Actionable Insight

The exchange offer reduces near-term debt maturity pressure at the subsidiary level, a modest credit positive. However, with a $28M market cap and no analyst bullish coverage, the parent company's equity remains highly speculative. Monitor for any parent-level debt restructuring or operational updates in upcoming 20-F filing.

Key Facts

Rizobacter completed exchange offer and consent solicitation on May 29, 2026.
Participation of ~86% of total outstanding principal amount of Series IX Class A, IX Class B, X Class A, and X Class B notes.
Transaction relates to ~US$42.7 million aggregate principal amount of existing notes.
Part of Rizobacter's broader liability management and maturity extension efforts.
Filing is a 6-K by foreign private issuer Bioceres Crop Solutions Corp. (BIOX).

Financial Impact

~US$42.7 million in notes restructured; 86% participation rate indicates strong creditor support for maturity extension.

debtliquidity

Risk Factors

Exchange offer details (new terms, maturity extension length) not disclosed; may involve higher interest costs or dilution.
Parent company's small market cap and lack of analyst support suggest limited equity upside from subsidiary-level debt management.
Argentine macroeconomic and currency risks for Rizobacter's operations.

Market Snapshot

Exchange

Nasdaq

Sector

Agricultural Chemicals

Analyst Consensus

0% bullish (6 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001104659-26-068690
Document: 0001104659-26-068690-index-headers.html	0001104659-26-068690
Document: 0001104659-26-068690-index.html	0001104659-26-068690
Document: 0001104659-26-068690.txt	0001104659-26-068690

US Market Status

Market Closed — Opens in 5h 12m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access